Inhaled corticosteroids for recurrent XXXX in preschool @entity1 in general practice: randomized controlled trial.

@entity1 @entity1353 @entity565 @entity4185 @entity1576 @entity5023
BACKGROUND: Therapy with @entity4185 ( @entity4185 ) is beneficial in @entity1 with @entity565 . However, in preschool @entity1 with symptoms like cough, wheeze, or @entity1353 diagnosing @entity565 is difficult. Therefore, the role of @entity4185 in the management of preschool @entity1 with recurrent @entity1576 is unclear. We assessed the effectiveness of @entity4185 in preschool @entity1 with recurrent @entity1576 in general practice. METHODS: In this multicenter, randomized, double blind, placebo controlled trial, 96 @entity1 aged 1-5 years consulting their general practitioners for recurrent @entity1576 and in whom treatment with @entity4185 was considered by the general practitioner were randomly allocated to receive @entity4185 ( @entity5023 200 mcg/day by metered dose inhaler/spacer combination) or placebo for 6 months. Outcome assessments were carried out 1, 3, and 6 months after randomization. The primary outcome measure was the symptom score (cough, @entity1353 and wheeze during day and night) as measured by a symptom diary card. Secondary endpoints were symptom-free days, use of rescue medication, adverse events, and lung function variables as measured by the interrupter technique and forced oscillation technique. RESULTS: During the 6 months treatment period, symptoms improved in both groups, with no differences between @entity4185 and placebo. In addition, none of the secondary outcome parameters showed differences between both treatment groups. CONCLUSION: @entity4185 treatment has no beneficial effect in preschool @entity1 with recurrent @entity1576 in general practice. We therefore recommend a watchful waiting policy with only symptomatic treatment in these @entity1 . General practitioners and pediatricians should be aware of the high probability of overtreatment when prescribing @entity4185 in these @entity1 .
